Cancer survivors are increasingly reported to exhibit signs of accelerated aging, largely attributed to the cytotoxic effects of chemotherapy, which may lead to various age-related conditions. Despite this, treatment-induced alterations in physical appearance-particularly changes in skin structure-are often overlooked in clinical practice and remain poorly understood. This study aimed to elucidate the mechanisms by which cytotoxic anticancer drugs affect skin integrity, with a focus on collagen (type I and III) and elastin, key components associated with skin aging. In a murine model, dietary restriction alone, as well as treatment with each of the anticancer drugs used in this study (cisplatin, 5-fluorouracil, vincristine, irinotecan and cyclophosphamide), led to significant weight loss; however, dermal thinning was observed exclusively in the cisplatin and vincristine. This structural deterioration correlated with a pronounced downregulation of Col1a1, Col1a2, Col3a1, and Eln at both the mRNA and protein levels. Mechanistically, this was accompanied by suppression of the TGF-β/Smad signaling pathway, evidenced by reduced TGF-β expression and Smad2 phosphorylation. Furthermore, the gene expression of Loxl1 and Loxl2-enzymes critical for collagen and elastin cross-linking was significantly diminished. These findings suggest that cisplatin and vincristine compromise dermal architecture by disrupting TGF-β signaling and extracellular matrix homeostasis, potentially contributing to premature skin aging in cancer survivors.